The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

RheumNow News Highlights: 11 Agents That Cause Arthritis, Lupus - Te…

RheumNow

J. Cush

Year in Review: Lung Cancer

Balazs Halmos

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Clinical Approach to Diagnosis and Treatment of Cytokine Storm in Rh…

Cleveland Clinic Rheumatology

R. Q. Cron

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

Hair Graying and the Melanocyte: Mechanisms and Melanoma Implications

Masterclasses in Dermatology

D. Fisher

Checkpoint Inhibitors and Rheumatic Disease

NYU Langone

A. Bass

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson